All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
  Â
Rybelsus 7mg Tablet
Prescription Required
Salt Composition : Semaglutide
Manufacturer : NOVO NORDISK INDIA PVT LTD
Origin of Medicine : Denmark
10 Tablet(s) In A Strip
Introduction to Rybelsus 7mg Tablet
Rybelsus 7mg tablet contains active components such as Semaglutide. This medication belongs to a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This medication treats type 2 diabetes by lowering blood sugar levels and promoting weight loss. It also reduces the risk of cardiovascular events in high-risk diabetes patients. It can be combined with other diabetes medications for better control and may lower blood pressure, benefitting cardiovascular health. Additionally, it shows potential in protecting kidneys and slowing diabetic kidney disease progression.
Â
You should not take Rybelsus 7mg tablet if you have a known hypersensitivity to this medication or any of its components. People with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not take this medication. It is not approved for use in pediatric patients with type 2 diabetes. It should not used in individuals with a history of severe gastrointestinal disease, such as gastroparesis. This medication is not recommended for individuals with severe renal impairment or end-stage renal disease.
Uses of Rybelsus 7mg Tablet
Rybelsus 7mg tablet is used to treat the following:
- Type 2 diabetes mellitus
- Obesity or overweight.
Therapeutic Effects of Rybelsus 7mg Tablet
Rybelsus 7mg tablet, a GLP-1 receptor agonist, exerts its therapeutic effects by mimicking the action of the naturally occurring hormone GLP-1. In diabetes management, this medication enhances insulin secretion, inhibits glucagon release, slows gastric emptying, and decreases hepatic glucose production. This medication effect leads to improved glycemic control and reduced HbA1c levels. Additionally, this medication promotes weight loss through increased satiety, decreased food intake, and modulation of gastric function. It has also demonstrated cardiovascular benefits, including a potential reduction in major cardiovascular events.
Interaction of Rybelsus 7mg Tablet with other drugs
Inform the doctor about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Rybelsus 7mg tablet, reducing effectiveness by causing undesirable side effects.Â
More Information about Rybelsus 7mg Tablet
- Stored in a refrigerator from 2°C to 8°C.
- Keep away from moisture, heat, and light.
- It should not be frozen.
- Keep away from children and pets.
How to consume Rybelsus 7mg Tablet
Rybelsus 7mg tablet is typically administered as a subcutaneous injection. The injection can be given in the abdomen, thigh, or upper arm. These medication pens come with clear instructions on how to load the needle, dial the dose, and administer the injection. After injecting, dispose of the needle safely in a sharps container. Regular monitoring and follow-up with your healthcare provider are important to assess your progress and make any necessary adjustments to your treatment plan.
Safety Advices for Rybelsus 7mg Tablet
 Â
Pregnancy
 Â
Rybelsus 7mg tablet is not recommended if you are pregnant or planning to become pregnant, consult your healthcare provider before using it.
 Â
Breast Feeding
 Â
If you are breastfeeding, consult your healthcare provider before using Rybelsus 7mg tablet, as its efficacy and safety in breastfeeding are unknown.
 Â
Lungs
  Rybelsus 7mg tablet should be used cautiously in individuals with severe lung disease. If you have any lung or lung conditions, discuss the risks and benefits of Rybelsus 7mg tablet with your healthcare provider before starting treatment.
 Â
Liver
  Rybelsus 7mg tablet should be used cautiously in individuals with severe liver disease. If you have any lung or liver conditions, discuss the risks and benefits of Rybelsus 7mg tablet with your healthcare provider before starting treatment.
 Â
Alcohol
 ÂAlcohol can affect blood sugar levels and potentially interfere with diabetes management. Consult your healthcare provider regarding alcohol consumption while using Rybelsus 7mg tablet.
 Â
Driving
  Rybelsus 7mg tablet is not known to cause drowsiness or impair cognitive function. However, if you experience any side effects that may affect your ability to drive or operate machinery, such as dizziness or hypoglycemia (low blood sugar), use caution and consult your doctor.
Side Effects of Rybelsus 7mg Tablet
Rybelsus 7mg tablet causes some side effects like all medications, although not everyone will experience them.Â
Serious
- Allergic reactions
- Pancreatitis (abdominal pain, nausea, vomiting)
- Hypoglycemia (low blood sugar)
- Kidney problems (changes in urination, swelling in the ankles or feet)
- Thyroid C-cell tumors
Common
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Decreased appetite
- Headache
- Fatigue
- Injection site reactions (e.g., redness, pain, itching)
Word of Advice
Discuss your medical history with your healthcare provider, especially if you have a history of pancreatitis, thyroid issues, kidney or liver problems, or gallbladder disease. Monitor your blood sugar levels regularly to avoid hypoglycemia, particularly when taking other antidiabetic medications. Adhere strictly to the prescribed dosage and injection schedule, and follow proper injection techniques to minimize risks. Its injections may cause skin reactions at the injection site. Rotate injection sites and follow proper injection techniques to minimize this risk. Report any unusual symptoms, such as abdominal pain or skin reactions, promptly to your healthcare provider. Pregnant and breastfeeding women should consult a doctor before taking this medication. Regularly assess your overall health and any potential changes while using Rybelsus 7mg tablet, and attend follow-up appointments as your healthcare provider recommends.
FAQs
Q 1. What are the common side effects of Rybelsus 7mg tablet?
Common side effects may include nausea, vomiting, diarrhea, decreased appetite, headache, and injection site reactions.
Q 2. Can Rybelsus 7mg tablet cause Pancreatitis?
There is a potential risk of pancreatitis with Rybelsus 7mg tablet. Seek medical attention if you experience severe abdominal pain.
Q 3. Who should not use Rybelsus 7mg tablet?
Rybelsus 7mg tablet is contraindicated in individuals with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Those with a hypersensitivity to this medication should also avoid its use.
Q 4. Can Rybelsus 7mg tablet affect my thyroid health?
Yes, Rybelsus 7mg tablet has been associated with thyroid C-cell tumors in animal studies. Individuals with a history of thyroid conditions or MTC should discuss the potential risks with their healthcare provider.
Q 5. How can I minimize the risk of hypoglycemia while using Rybelsus 7mg tablet?
Rybelsus 7mg tablet, especially when used with other antidiabetic medications, can increase the risk of hypoglycemia (low blood sugar). Monitoring your blood sugar levels closely and following your healthcare provider's guidance can help manage this risk.
Q 6. Is Rybelsus 7mg tablet safe for individuals with kidney problems?
Rybelsus 7mg tablet should be used cautiously in individuals with kidney impairment. Dose adjustments may be necessary based on your kidney function.
Q 7. What should I do if I develop gallbladder symptoms while taking Rybelsus 7mg tablet?
Rybelsus 7mg tablet has been associated with gallbladder-related events. Seek medical attention if you experience symptoms like sudden abdominal pain, particularly in the upper right side.
Fact Box of Rybelsus 7mg Tablet
Molecule name: Semaglutide  | Therapeutic class: Hypoglycemic Drug |
Pharmacological class: Glucagon-like peptide-1 receptor agonists
| Indications: 1. Type 2 diabetes mellitus  2. Obesity or overweight |
References
- Novo Nordisk Inc, FDA Food and Drug Safety Administration [September 20, 2019] [Accessed date 18th August 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf
- Novo Nordisk Limited, EMC, [25 Jan 2023], [Accessed date 18th August 2023] Electronic Medicines Compendium (EMC), [Revised on 25th Jan 2023] [Accessed on 18 August 2023]https://www.medicines.org.uk/emc/product/11507/pil
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
